Skip to main content
main-content

05.06.2019 | Head and Neck | Ausgabe 7/2019

European Archives of Oto-Rhino-Laryngology 7/2019

The growth rate and the positive prediction of needle biopsy of clinically diagnosed Warthin’s tumor

Zeitschrift:
European Archives of Oto-Rhino-Laryngology > Ausgabe 7/2019
Autoren:
Jungirl Seok, Woo-Jin Jeong, Soon-Hyun Ahn, Young Ho Jung
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00405-019-05493-7) contains supplementary material, which is available to authorized users.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

This study reports the clinical course, including the growth rate, of Warthin’s tumor (WT) and evaluates the positive prediction of needle biopsy for WT.

Methods

The medical records of 182 patients clinically diagnosed with WT were retrospectively reviewed. Tumor growth rates were measured in patients who underwent serial radiologic exams with minimum 6-month time intervals, and the positive prediction value (PPV) of needle biopsy was evaluated in comparison with surgical pathology in patients who underwent surgical excision of the tumors.

Results

Serial radiologic exams were available for growth rate measurement in 31 tumors (size 0.7–9.1 cm) from 25 patients. Among these, 24 tumors increased in size, and 7 were stable. The median follow-up duration was 23.5 months [interquartile range (IQR) 14.8–51.9], and the tumor growth rate ranged from − 0.36 to 2.26 cm per year (median 0.26, IQR 0.07–0.44). Needle biopsy results were available for comparison with postoperative pathology specimens in 147 patients. The PPV was 97.7% for fine-needle aspiration biopsy and 100% for core-needle biopsy. There were no reports of inflammation, facial nerve paralysis, or admission event during the follow-up.

Conclusions

WT glows slowly and can be predicted by needle biopsy. Therefore, parotid masses diagnosed as Warthin’s tumor can be treated or left untreated based on the patient's needs and clinical decision-making.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary file1 (DOCX 62 kb)
405_2019_5493_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2019

European Archives of Oto-Rhino-Laryngology 7/2019 Zur Ausgabe
  1. Sie können e.Med HNO 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet HNO

19.08.2019 | Neues aus der Industrie | Onlineartikel

Was kann die Arztpraxis von der Klinik lernen?

13.08.2019 | GOÄ | AUS DER PRAXIS VON HAUSARZT ZU HAUSARZT | Ausgabe 14/2019

So wird ab 2020 die Leichenschau berechnet

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise